FOR IMMEDIATE RELEASE

Date: March 31, 2004

Burlington, Ontario

The Jenex Corporation (“Jenex”) [TSXV:JEN] the company which has developed the first clinically proven and approved patented thermal therapeutic device for the prevention of cold sores, is pleased to announce the appointment of The Gibson Group as its advertising agency of record.

GRANT GIBSON, President of The Gibson Group said, “We are delighted to be working with Jenex.  The Company’s cold sore prevention device has a huge worldwide potential. At last cold sore sufferers can actually prevent an outbreak rather than just treat the symptoms. This will revolutionize the way cold sores are treated.”

The Gibson Group will be responsible for advertising and marketing activities for Jenex including design, creative, media and marketing materials.

Michael Jenkins, President and CEO of Jenex said, “Jenex is very pleased to have The Gibson Group as part of our team. The Gibson Group has extensive experience in consumer and healthcare marketing and advertising. They will play an important role in the launch of our cold sore prevention product in 2004 and the future growth of Jenex.”

About the Jenex Corporation

Headquartered in Burlington, Ontario, the Corporation has developed and patented a thermal therapeutic device for the prevention of cold sores. Patents in fifteen countries, including the United States, Canada, Australia, and the E.E.C protect the technology. The Corporation is preparing to launch their cold sore prevention device in the Canadian market in late 2004. Jenex has clearance to market the cold sore device in Canada with their approved claim “For prevention and relief of the symptoms of herpes labialis (cold sores), such as blistering, lesions, inflammation, and discomfort. Also helps alleviate the embarrassment that is typically associated with herpes labialis (cold sore) outbreaks”. Regulatory approvals will be pursued for USA, Europe and Australia.  The HSV-1 virus that causes cold sores, is endemic in North America, and is estimated to affect 80% of the population. For 20% to 40% of the population, their cold sore outbreaks are recurrent. As the only product clinically proven to prevent the outbreak of cold sores, the Corporation's thermal therapy product has the potential to dominate a large and underdeveloped market.

About The Gibson Group

The Gibson Group is a full service advertising and marketing firm that specializes in consumer/healthcare products. With over 25 years of experience and a wide array of clients, The Gibson Group has a proven track record for bringing sustained growth to their clients.

For more about The Gibson Group visit www.thegibsongroup.ca

The TSX Venture Exchange Inc. has not reviewed and does not accept responsibility for the accuracy or the contents of this press release.  Certain information included in this press release is forward-looking and is subject to important risks and uncertainties.  The results or events predicted in these statements may differ materially from actual results or events.

For further information, please contact:

The Jenex Corporation
Michael Jenkins - President
Phone:  905-632-3830
Email:  jenex@sprint.ca
Fax:  905-632-3774
940 Sheldon Court, Suite 207
Burlington, Ontario Canada
L7L 5K6